Share Purchase Agreement between Entest Group, Inc. and Zander Therapeutics, Inc. for Regen Biopharma Series A Preferred Shares

Contract Categories: Business Finance › Purchase Agreements
Summary

Entest Group, Inc. agrees to sell 3,500,000 Series A preferred shares of Regen Biopharma, Inc. to Zander Therapeutics, Inc. for $35,000 in cash. The shares are confirmed to be free of any encumbrances and can be transferred to the buyer. The agreement is signed by both parties' CEO, David Koos. The latest closing price of the shares is noted as $0.028 per share, with a total market value of $98,000.

Read More Arrow
EX-10.1 2 ex10_1.htm EXHIBIT 10.1

 

ENTEST GROUP, INC. AND ZANDER THERAPEUTICS, INC. AGREEMENT

Zander Therapeutics, Inc. agrees to purchase 3,500,000 Series A preferred Shares of Regen Biopharma, Inc. (“Shares”) from Entest Group, Inc. (“Owner”) for the price of $35,000 USD cash. Latest closing price for these shares is .028 US$ per share or total value of $98,000.

Owner acknowledges that Shares are free of any encumbrances and able to be transferred to Zander Therapeutics, Inc.

Signed in Agreement:

/s/David Koos    
By: David Koos, CEO    
ENTEST GROUP,INC.    
     
/s/David Koos    
By: David Koos, CEO    
ZANDER THERAPEUTICS, INC.